Articles
By Wayne Kuznar
Combining an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) significantly improved progression-free survival (PFS) in treatment-naïve patients with advanced renal-cell carcinoma (RCC) compared with a TKI alone. Read More ›
The February issue of The Oncology Pharmacist (TOP) features presentations and studies from national and international meetings, including the 2018 Palliative and Supportive Care in Oncology Symposium, the European Society for Medical Oncology (ESMO) 2018 Congress, and the 2018 International Association for the Study of Lung Cancer World Conference on Lung Cancer. Read More ›
Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations
Udenyca, Second Biosimilar to Neulasta, FDA-Approved to Reduce Risk for Infection in Patients with Nonmyeloid Malignancies
Daurismo New Treatment Approved for Older Adults with Acute Myeloid Leukemia
Xospata First Therapy Approved for Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Truxima First Biosimilar to Rituxan FDA-Approved for Non-Hodgkin Lymphoma Read More ›
Udenyca, Second Biosimilar to Neulasta, FDA-Approved to Reduce Risk for Infection in Patients with Nonmyeloid Malignancies
Daurismo New Treatment Approved for Older Adults with Acute Myeloid Leukemia
Xospata First Therapy Approved for Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Truxima First Biosimilar to Rituxan FDA-Approved for Non-Hodgkin Lymphoma Read More ›
Adcetris First FDA-Approved Drug for CD30-Expressing Peripheral T-Cell Lymphomas
Venclexta Approved in Combination for Older Adults with Acute Myeloid Leukemia Read More ›
Venclexta Approved in Combination for Older Adults with Acute Myeloid Leukemia Read More ›
Recent results with the investigational targeted therapy alpelisib, a PI3K inhibitor, showed impressive clinical benefits. Adding alpelisib to fulvestrant (Faslodex) extended progression-free survival (PFS) compared with endocrine therapy alone in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer characterized by a PIK3CA mutation. Read More ›
The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Read More ›
Treatment options are few for patients with cholangiocarcinoma whose disease progresses while receiving first-line treatment with gemcitabine (Gemzar) and cisplatin (Platinol), with no established second-line regimen. Read More ›
Long-term therapy with olaparib (Lynparza), a poly (ADP ribose) polymerase (PARP) inhibitor, in women with newly diagnosed advanced ovarian cancer and a BRCA1 or BRCA2 mutation led to a significant, unprecedented improvement in progression-free survival (PFS), reducing the risk for disease progression or death by 70% compared with placebo, according to results of the phase 3 SOLO-1 clinical trial. Read More ›
Although many new treatments, including targeted therapies and immunotherapies, have recently become available for patients with non–small-cell lung cancer, those with small-cell lung cancer have not seen new treatment options in the past 2 decades. But this is about to change. Read More ›
Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold. Read More ›